Cardiovascular Diseases Clinical Trial
Official title:
The Effects of a Cardiovascular Health Education Program on Community-dwelling Older Adults at Risk of Atherosclerotic Cardiovascular Diseases: A Pilot Randomized Controlled Trial
Despite older adults being exposed to an increased risk of atherosclerotic cardiovascular disease (ASCVD), they are generally underrepresented in cardiovascular prevention programmes. The aim of this study is to assess the feasibility of implementing an integrated exercise and cardiovascular health education programme (HE programme) on older adults at risk of ASCVD.
Status | Not yet recruiting |
Enrollment | 80 |
Est. completion date | September 1, 2024 |
Est. primary completion date | September 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years and older |
Eligibility | Inclusion Criteria: - Chinese adults ?60 years old - Having at least one ASCVD risk factor - Pass the cardiovascular fitness evaluation - Able to write and read Chinese, and communicate in Cantonese; - Possess a mobile phone and able to make use of the phone in reading SMS Exclusion Criteria: - Visually impaired, hearing impaired, or suffer from cognitive, psychiatric, or muscular disorder - Having a history of attending similar cardiovascular prevention program - Having a previous history of coronary heart disease or stroke |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
The Hong Kong Polytechnic University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Physical activity level (total score) | The physical activity level will be measured by the Chinese Version of Physical Activity Scale for the Elderly (PASE-C). The total score (from zero to 400 or above) is quantified based on frequency values and weights for these activities. The higher the score, the higher the level of physical activity. | At baseline, at Week 6, and at Week 12 | |
Primary | Physical activity level (classification of physical activity level) | The physical activity level will be measured by the Chinese version of International Physical Activity Questionnaire-short form (IPAQ-C-short form). Participants are classified into "inactive", "minimally active" or "health enhancing physical activity (HEPA) active" based on their physical activity levels. | At baseline, at Week 6, and at Week 12 | |
Secondary | Exercise self-efficacy | Exercise self-efficacy will be measured via the Chinese version of Self-Efficacy for Exercise (SEE-C). The total score ranges from 0 to 90. The higher the score, the greater the exercise self-efficacy. | At baseline, at Week 6, and at Week 12 | |
Secondary | ASCVD risk profiles (Blood pressure, weight, height, BMI & waist circumference, heart rate) | The ASCVD risk profiles will be assessed by physical evaluations carried out by blinded, trained outcome assessors. | At baseline, at Week 6, and at Week 12 | |
Secondary | ASCVD risk profiles (2-minute walk test) | 2-minute walk test will be adopted to examine aerobic capacity and self-paced walking capacity by measuring the walking distance covered at two minutes. It will be assessed by blinded, trained outcome assessors. | At screening stage, at Week 6, and at Week 12 | |
Secondary | Acceptability of the program to participants | It will be measured by a self-developed questionnaire | At Week 12 | |
Secondary | Acceptability of the program to outcome assessors | It will be measured by a self-developed questionnaire completed by outcome assessors | After the outcome assessors have finished their duties | |
Secondary | Acceptability of the program to lecture deliverers | It will be measured by a self-developed questionnaire completed by lecture deliverers | After the lecture deliverers have finished their duties | |
Secondary | Adverse events throughout the program | Unfavorable or unintended events regarding the programme reported by participants throughout the study period. | Throughout the study period | |
Secondary | Program safety evaluated by participants | It will be measured via a self-developed questionnaire completed by participants | At Week 12 | |
Secondary | Eligibility rate | The number of eligible potential participants divided by the number of screened people | At baseline | |
Secondary | Recruitment rate | The percentage of participants who consent to join the study and being recruited | At baseline | |
Secondary | Retention rate | The percentage of participants remaining in the study | At baseline, at Week 6 and at Week 12 | |
Secondary | Lecture attendance rate | The number of participants in the control group who attend the education talk divided by the number of participants who are randomized into the control group
The number of participants in the experimental group who attend the education session divided by the number of participants who are randomized into the experimental group The number of participants in the two groups who attend the education session divided by the number of randomized participants |
Immediately after education session | |
Secondary | Adherence to intervention | The number of participants in the experimental group who practice the tailor-made exercise learned during the intervention divided by the number of participants in the experimental group
Experimental group's frequency in performing tailor-made exercise related to the recommended exercise dosage |
At Week 6 and at Week 12 | |
Secondary | Attendance rate to data collection | The number of participants in the control group who attend the data collection divided by the number of participants who are randomized into the control group
The number of participants in the experimental group who attend the data collection divided by the number of participants who are randomized into the experimental group The number of participants who attend the data collection divided by the number of randomized participants |
At baseline, at Week 6 and at Week 12 | |
Secondary | Questionnaire completion rate | The number of participants who complete the questionnaire divided by the number of distributed questionnaires | At baseline, at Week 6 and at Week 12 | |
Secondary | Missing data | The percentage of missing data | At baseline, at Week 6 and at Week 12 | |
Secondary | Structured questionnaire | The questionnaire will primarily include patient demographics, medical history, lifestyle patterns, medication use and physical fitness evaluation data, etc. | At baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|